您的位置: 首页 > 农业专利 > 详情页

Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
专利权人:
Novartis AG
发明人:
CONG, Feng,RANGWALA, Shamina M.,ETTENBERG, Seth,GUTH, Sabine
申请号:
AU2013204217
公开号:
AU2013204217A1
申请日:
2013.04.12
申请国别(地区):
AU
年份:
2013
代理人:
摘要:
#$%^&*AU2013204217A120130502.pdf#####H:\fmt\Intenvven\NRPortb\DCC\FM\$068994-1.DOC-1l/04/2013 ABSTRACT The invention discloses LRP6 agonizing or antagonizing binding molecules (e.g., antibodies or a Fab fragments), and their use to facilitate or inhibit Wnt pathway signaling, respectively. Said LRP6 agonizing or antagonizing binding molecules can be used to e.g., diagnose, ameliorate the symptoms of, protect against, and treat Wnt signaling disorders associated with aberrantly low or aberrantly high levels of Wnt pathway signaling, respectively. Non-limiting examples of disorders which can be treated associated with aberrant upregulation of Wnt signaling is cancer (e.g., colon cancer). Non-limiting examples of disorders which can be diagnosed, protected against, and treated include cancers, bone disorders (e.g., osteoporosis and osteoarthritis), diabetes, neurodegenerative diseases such as Alzheimers disease, and fibrotic disorders.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充